- Conditions
- Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin, Olaparib, Niraparib
- Drug
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 9
- States / cities
- Orlando, Florida • New Orleans, Louisiana • Minneapolis, Minnesota + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1105–1128
of 2,462
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Interventions
- Fludarabine, Cyclophosphamide, NK cells, IL-2, INCB024360
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Breast Cancer, Cancer, Carcinoma, Renal Cell, Lymphoma, Ovarian Cancer
- Interventions
- PSC 833, paclitaxel
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
- Interventions
- Zanidatamab
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 17
- States / cities
- Prescott, Arizona • Littleton, Colorado • Fort Myers, Florida + 14 more
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Omega Nutrition cold-milled flaxseeds
- Drug
- Lead sponsor
- Southern Illinois University
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Springfield, Illinois
- Conditions
- Ovarian Carcinoma
- Interventions
- docetaxel
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Malignant Ovarian Epithelial Tumor, Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Sex Cord-Stromal Tumor, Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types, Ovarian Steroid Cell Tumor
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 36
- States / cities
- Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 24 more
- Conditions
- Ovarian Cancer, Fatigue, Coping Behavior, Coping Skills
- Interventions
- Enhanced Usual Care (EOC), REVITALIZE ACT Intervention
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma
- Interventions
- TROP2-CAR-NK, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ovarian Cancer
- Interventions
- Ad5.SSTR/TK.RGD, Ganciclovir (GCV)
- Genetic · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Interventions
- bryostatin 1, cisplatin, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms
- Interventions
- Not listed
- Lead sponsor
- The Canadian College of Naturopathic Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Kailua, Hawaii • Fife, Washington + 2 more
- Conditions
- Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
- Interventions
- COM701 in combination with BMS-986207 and nivolumab.
- Drug
- Lead sponsor
- Compugen Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 6 more
- Conditions
- Gynecologic Cancer, Ovarian Cancer, Endometrial Cancer, Uterine Cancer, Cervical Cancer
- Interventions
- Group pre-operative counseling
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer
- Interventions
- goserelin, letrozole, leuprolide acetate, conventional surgery
- Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer
- Interventions
- capecitabine, brachytherapy, radiation therapy
- Drug · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Ovarian Cancer
- Interventions
- filgrastim, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
- Biological · Procedure · Radiation
- Lead sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 3
- States / cities
- Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Hereditary Breast and Ovarian Cancer Syndrome
- Interventions
- Culturally-Targeted Video, FORCE Fact Sheet
- Behavioral · Other
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Alexandria, Virginia • Arlington, Virginia + 1 more
- Conditions
- Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Interventions
- imatinib mesylate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Interventions
- rV-NY-ESO-1 vaccine, rF-NY-ESO-1 vaccine
- Biological
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Ovarian Cancer
- Interventions
- Follicle Stimulating Hormone Receptor T Cells
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Ovarian Cancer
- Interventions
- Group Session, Telephone Coaching Session, Webinar
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor, Kidney Tumor
- Interventions
- doxorubicin HCl liposome
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Timeline
- Started 1999
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Philadelphia, Pennsylvania
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Interventions
- cisplatin, liposomal doxorubicin, paclitaxel
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Female only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 104
- States / cities
- Tucson, Arizona • Davis, California • Duarte, California + 66 more